Hansa Biopharma announces positive results from NICE-01 trial of next generation IgG-cleaving molecule, HNSA-5487: Lund, Sweden Tuesday, October 8, 2024, 11:00 Hrs [IST] Hansa Bio ...
Hansa Biopharma AB, ("Hansa" or the "Company") (NASDAQ STOCKHOLM: HNSA), today announced positive results from a 12-month follow up analysis from the NICE-01 trial of HNSA-5487, the Company's next ...